Trial Search Results
Genome Transplant Dynamics: Non-invasive Sequencing-based Diagnosis of Rejection
The purpose of this study is to determine whether shotgun sequencing technology, which can be used to detect donor DNA in recipient plasma, can be used as a rapid, accurate, non-invasive method to detect Acute Cellular Rejection (ACR) after heart transplantation. Currently, all heart transplant recipients undergo invasive heart biopsies to diagnose ACR. Thus, there is an ongoing need to monitor patients for the development of acute and chronic rejection, with the primary goal of non-invasive early detection and treatment to prevent organ damage.
Stanford is currently not accepting patients for this trial.
Collaborator: Kaiser Foundation Research Institute
1. All ages of heart or lung transplant recipients
2. Recipients of re-do heart or re-do lung transplants
1. Patients wait-listed for multiple organ transplantation (e.g. heart-kidney,
heart-liver, heart and lung.)
2. Unable or unwilling to return to Stanford for biopsy and follow-up procedures
3. Followed by Palo Alto VA Hospital after transplant surgery (VA patients are
transplanted at Stanford, but all subsequent clinical care is performed at VA
Ages Eligible for Study
N/A - N/A
Genders Eligible for Study